Clinical stage biotechnology company MiNK Therapeutics wrapped its initial public offering, selling 3.333 million shares at $12 each, the low end of its $12 to $14 range.
Shares of INKT will commence trading on the Nasdaq later today, but the stock is available for limit orders on Robinhood and other platforms.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.60 |
|---|---|
| 52-week range | $4.56 - $13.79 |
| 50-day moving average | $8.46 |
| 200-day moving average | $8.00 |
| Wall St. target price | $48.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.86 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.6 from 2025-05-02
| 1 week (2025-04-28) | 1.33% |
|---|---|
| 1 month (2025-04-04) | -9.63% |
| 3 months (2025-02-06) | -31.53% |
| 6 months (2024-11-06) | 937.83% |
| 1 year (2024-05-06) | 707.91% |
|---|---|
| 2 years (2023-05-05) | -51.90% |
| 3 years (2022-05-05) | 20.7 |
| 5 years (2020-05-02) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -137.35% |
| Return on equity TTM | -1238.98% |
| Profit margin | 0% |
| Book value | $-4.94 |
| Market Capitalization | $29.7 million |
TTM: trailing 12 months
We're not expecting MiNK Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
MiNK Therapeutics's shares were split on a 1:10 basis on 27 January 2025 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MiNK Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for MiNK Therapeutics shares which in turn could have impacted MiNK Therapeutics's share price.
Over the last 12 months, MiNK Therapeutics's shares have ranged in value from as little as $4.5601 up to $13.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MiNK Therapeutics's is 0.145. This would suggest that MiNK Therapeutics's shares are less volatile than average (for this exchange).
To put MiNK Therapeutics's beta into context you can compare it against those of similar companies.
MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.